# Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00624286** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 416 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Indacaterol 150 μg
- **DRUG:** Placebo to indacaterol

## Key facts

- **NCT ID:** NCT00624286
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2011-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00624286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00624286, "Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00624286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*